Clinical Trial Eligibility Dashboard

Matching patients to clinical trials using AI-powered analysis

Active Clinical Trials

5 trials available for patient matching • Selected: Novel GLP-1 Agonist for Type 2 Diabetes

Phase 3
Novel GLP-1 Agonist for Type 2 Diabetes
NovoMed Pharmaceuticals

Protocol ID

CT-2024-DM-001

Research Aim

Evaluate efficacy and safety of investigational GLP-1 receptor agonist in reducing HbA1c levels and promoting weight loss in adults with Type 2 diabetes inadequately controlled on metformin monotherapy.

Demographics

Age: 18-65 years

Gender: Male, Female

Key Conditions: Type 2 Diabetes Mellitus, HbA1c 7.0-10.5%...

Enrollment247 / 450
Phase 2/3
Extended-Release Naltrexone Plus Brief Cognitive Behavioral Intervention for Stress-Triggered Hazardous Drinking
CardioGenix Therapeutics

Protocol ID

CT-2024-CV-018

Research Aim

Evaluate the efficacy and safety of monthly extended-release naltrexone in combination with a brief, manualized CBT intervention (4 sessions) to reduce heavy drinking days and improve functioning in adults who engage in stress-triggered hazardous drinking with comorbid anxiety/depressive symptoms.

Demographics

Age: 20-65 years

Gender: Male, Female

Key Conditions: Moderate Alcohol Use Disorder (DSM-5) or hazardous episodic heavy drinking (≥4 heavy drinking days in past 30 days), Self-reported stress-triggered drinking related to work/family stressors...

Enrollment89 / 200
Phase 2
Oral Factor XIa Inhibitor (FXIaX) Versus Standard Direct Oral Anticoagulant Therapy for Acute Symptomatic Pulmonary Embolism
Hepatica BioPharma

Protocol ID

CT-2024-NASH-005

Research Aim

Compare the efficacy and safety of an investigational oral Factor XIa inhibitor (FXIaX) to standard-of-care direct oral anticoagulant (DOAC) therapy for reduction of recurrent venous thromboembolism (VTE) and major bleeding in adults presenting with acute symptomatic pulmonary embolism (PE).

Demographics

Age: 18-70 years

Gender: Male, Female

Key Conditions: Confirmed acute symptomatic pulmonary embolism on imaging (CT pulmonary angiography or V/Q) within 72 hours of randomization, May have concomitant symptomatic proximal deep vein thrombosis (DVT)...

Enrollment34 / 150
Phase 3
Acute Positional Vertigo Evaluation and Management
ImmunoThera Sciences

Protocol ID

CT-2024-RA-042

Research Aim

Assess and document clinical features of sudden-onset positional vertigo and evaluate response to positional maneuvers such as the Epley maneuver.

Demographics

Age: 18-75 years

Gender: Male, Female

Key Conditions: Acute onset vertigo, Positional dizziness triggered by head movement...

Enrollment312 / 600
Phase 3
Amyloid-Beta Monoclonal Antibody for Early Alzheimer's
NeuroCog Research Group

Protocol ID

CT-2024-AD-029

Research Aim

Determine whether monthly IV infusions of anti-amyloid-beta monoclonal antibody can slow cognitive decline measured by CDR-SB in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease with confirmed amyloid pathology.

Demographics

Age: 50-85 years

Gender: Male, Female

Key Conditions: MCI or mild AD dementia, Positive amyloid PET scan...

Enrollment891 / 1500
Patient Roster

5 of 6 patients match trial criteria

Sarah Johnson

MRN-2024-001

92%

High Eligibility

Age

45 years

Gender

Female

Last Visit

11/10/2024

Add this patient to the enrollment pipeline

No assessment available for this patient-trial combination

Select a different trial or patient to view cached assessments